血管内皮细胞生长因子可溶性受体在肾脏疾病中的意义被引量：1

下载PDF

导出

摘要众所周知,由于肾小球特殊的毛细血管丛结构,血管内皮细胞的结构、功能及其调节在肾脏疾病中具有重要意义。如糖尿病肾病患者,其肾小管周围的毛细血管减少,并伴有血管内皮细胞损伤。血管内皮细胞生长因子（VEGF）是一种促进内皮细胞的增殖、迁移、增强血管通透性的细胞因子。VEGF通过促进肾周血管的新生不仅能减轻对肾脏的损害,甚至还能恢复肾脏功能[1]。因此VEGF及其受体的表达在肾脏疾病中发挥着重要的作用。现就综述如下。

作者安圆圆孙立

机构地区中国医科大学

出处《中国医学工程》 2015年第8期201-202,204,共3页 China Medical Engineering

关键词血管生长因子肾脏

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献22

1钟建,李夏露.血管内皮生长因子在肾纤维化血管新生中的作用研究进展[J].广西中医药大学学报,2013,16(2):121-123. 被引量：1
2Kim NH,Jung HH,Cha DR,et al.Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells[J].J Endocrinol,2000,165(3):617-624.
3Masabumi Shibuya.Vascular endothelial growth factor and its receptor system:physiological functions in angiogenesis and pathological roles in various diseases[J].J. Biochem,2013,153(1):13-19.
4Johanna E.Lahteenvuo,MD;Markku T.Lahteenvuo,MD; antti Kivela,MD et al.Vaseular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-I and neuropilin receptor-1 dependent mechanisms[J].Circulation,2009,119: 845-856.
5Kendall RL,Wang G,Thomas KA.Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR[j]. Biochem Biophys Res Commun, 1996,226:324 -328.
6Maynard SE,Min JY,Merchan J,et al.Excess placental soluble fms-like tyrosine kinase 1 (sFhl) may contribute to endothelial dysfunction, hypertension,and proteinuria in preeelampsia[J].J Clin Invest,2003,111: 649-658.
7Michael L.Gagnon,Diane R.Bielenberg,Zeev Geehtman,et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity[J]. 2000.97(6/:2573-2578.
8Uniewicz KA,Cross MJ,Femig DG.Exogenous Recombinant Dimeric Neuropilin-1 Is Sufficient to Drive Angiogenesis[J].J Biol Chem, 2011,286(1):12-23.
9Giovana S.Di Marco,Stefan Reuter,Uta Hillebrand,et al. The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in CKD[J].J Am Soc Nephrol,2009,20(10):2235-2245,.
10Hagmann H,Bossung V,Belaidi AA,et aLLow-molecular weight heparin increases circulating sFlt-I levels and enhances urinary elimination[J].PLoS One,2014,9(1).

二级参考文献23

1Senger D R, GaUi S J, Dvorak A M, et al . Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid [J].Science,1983,219 (4587):983-985.
2Houck K A, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA[J]. Mol Endocrinol, 1991,5(12):1806-1814.
3Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to ex- tracellular matrix [J]. J Biol Chem, 1997,272 (11):7151- 7158.
4Mei J,Gao Y,Zhang L,et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vas-culogenic mimicry in osteosarcoma in vitro[J]. Exp Oncol, 2008,30:29-34.
5Gerber H P, Hillan K J, Ryan A M, et al. VEGF is required forgrowth and urvival in neonatal mice [J]. Development, 1999, 126: 1149-1159.
6Napoleone Ferrara. VEGF-A: a critical regulator of blood vessel growth [J ]. European Cytokine Network,2009,20 (4): 158-163.
7Bihon R L , Booker G W . The subtle side to hypoxia in- ducible factor (HIFalpha)regulation [J].Eur J Biochem, 2003,270(5 ) : 791-798.
8Semenza G L.Hydroxylation of HIF-I: oxygen sensing at the molecular level[J]. Physiology(B ethesda), 2004, 19: 176-182.
9Pugh C W,Patcliffe P J.Regulation of angiogenesis by hy- Poxia:role of the HIF system[J].Nat.Med,2003,9(6):677- 684.
10Mazure N M, Brahimi-Hom M C, Pouyssegur J. Protein kinases and the hyPoxia-indueible factor-l,two switches inangiogenesis [ J ].Curr Pharm Des, 2003,9(7) :531-541.